Eur Urol:淋巴结阳性前列腺癌患者根治性前列腺切除术后生存结局:不同术后管理策略的比较分析。

2017-10-15 fengxiangxin MedSci原创

在本研究中,研究者评估了三种不同的管理策略与根治性前列腺切除术后发生淋巴结转移的患者的生存关系。

根治性前列腺切除术(RP)后淋巴结转移患者(LNM)的最佳管理策略尚未确定。

在本研究中,研究者评估了三种不同的管理策略与根治性前列腺切除术后发生淋巴结转移的患者的生存关系。

研究共纳入了来自三个三级保健中心的1338例RP后LNM患者的数据。387例患者接受了观察等待治疗(28%),676例患者接受终身辅助性雄激素剥夺治疗(ADT)(49%),325例(23%)患者接受辅助外放射治疗(EBRT)联合ADT。368名患者的随访时间超过10年。

主要结局指标为总生存期(OS),次要结局是癌症特异性生存率(CSS)和其他原因导致的死亡率。 Kaplan-Meier方法用于可视化比较三个治疗组的OS差异。 Cox比例风险回归分析用于比较三组之间的OS和CSS。

ADT + EBRT与单独使用ADT相比,有较好的OS([HR]:0.46,95%[CI]:0.32-0.66,p <0.0001),与主动监测相比也有较好的OS(HR:0.41,95%CI:0.27-0.64 ,p <0.0001)。在ADT + EBRT组中,高风险患者相比低风险患者受益更多。 三种策略(ADT + EBRT,观察等待和ADT)的十年死亡率风险差异从低风险患者的5%至高危患者的40%之间。

辅助ADT + EBRT与观察等待或单独ADT相比,CSS更好(p <0.0001)。与观察等待相比,ADT具有更好的CSS(HR:0.64,95%CI:0.43-0.95,p = 0.027)。然而,与观察等待相比,ADT与其他原因导致死亡的风险增加相关(HR:3.05,95%CI:1.45-6.40,p = 0.003),这导致ADT与观察等待之间出现相似的OS(HR:0.90,95% CI:0.65-1.25,p = 0.5)。

在RP后LNM患者中,ADT + EBRT较观察等待和单独ADT更好的提高了患者的生存率。并且这种生存益处随著高危风险的增加而增加。

原始出处:


本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-11-02 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-17 sodoo
  6. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1966945, encodeId=b6011966945e5, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 02 05:35:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988387, encodeId=b562198838ee1, content=<a href='/topic/show?id=18ae6365278' target=_blank style='color:#2F92EE;'>#比较分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63652, encryptionId=18ae6365278, topicName=比较分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Tue Apr 10 07:35:00 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708827, encodeId=f0081e088274e, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Tue Jun 26 14:35:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876954, encodeId=64ed18e695462, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Aug 15 19:35:00 CST 2018, time=2018-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293006, encodeId=beb61293006b2, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509990, encodeId=d25915099902f, content=<a href='/topic/show?id=735366030db' target=_blank style='color:#2F92EE;'>#淋巴结阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66030, encryptionId=735366030db, topicName=淋巴结阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590210187011, createdName=aids216, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586073, encodeId=ab0715860e348, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Tue Oct 17 05:35:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2017-10-17 jeanqiuqiu

相关资讯

J Urol: 前列腺癌发生率和前列腺特异抗原筛选流行度分析

在美国国家预防服务工作组(USPSTF)推荐的预防常规PSA工作之后,前列腺特异性抗原(PSA)筛选和前列腺癌发生率的减少是否与社会经济组织和美国人口普查区域之间是相似的这个问题仍旧不清楚。最近,有研究人员通过调查年龄、种族、疾病阶段、美国地区和区域社会经济状态分析了前列腺癌发生率和PSA筛选流行度。研究人员调查了年度百分比变化速率,并计算了边际概率和95%置信区间(CI)来评估PSA筛选流行度变

J Cancer:警惕!牙周病可增加前列腺癌的发病率!

由于人口老龄化,预计前列腺癌(PC)伴牙周病(PD)的发病率都会增加。本研究旨在通过使用国家健康保险服务-健康检查组(NHIS-HEC)中的数据来确定PD与PC之间的关联。2002年至2013年,通过随机分层抽样从NHIS数据库收集了187934名韩国人。在调整潜在的混杂因素(性别,年龄,家庭收入,保险状况,居住面积,高血压,糖尿病,脑梗塞,心绞痛,心肌梗塞,吸烟状况,酒精摄入和规律运动)的同时,

治疗特定前列腺癌,**新药有望近期上市

杨森(Janssen)公司今天宣布,该公司已经向FDA提交了一份新药申请,使用apalutamide(ARN-509),一款下一代口服雄激素受体抑制剂(AR),治疗非转移性去势抵抗性前列腺癌。目前,尚没有FDA批准的疗法针对此类疾病。

Eur Urol:比较醋酸阿比特龙和多西他赛联合雄激素剥夺治疗在高风险和转移性未经激素治疗的前列腺癌中的作用:系统评价与荟萃分析。

最近,随机临床试验已经验证了在使用激素剥夺疗法(ADT,使用波尼松/泼尼松龙)治疗未经激素治疗的晚期前列腺癌(PCa)时联合多西他赛或阿比特龙的益处。

Prostate:白花丹素可以提高治疗前列腺癌的雄激素疗法阻断效果

白花丹素是治疗前列腺癌的候选药物。之前的研究表明了白花丹素也许可以提高雄激素阻断疗法(ADT)的治疗效果。最近,有研究人员评估了将白花丹素和ADT结合在前列腺癌小鼠模型中进行试验,从而支持白花丹素的临床应用。研究人员利用新的芝麻油配方进行白花丹素口腔服用,并在小鼠中进行了标准的毒性研究。对肿瘤生长研究,研究人员将小鼠前列腺癌细胞团嫁接到前列腺组织上来形成肿瘤。小鼠被分成不同处理的小组,肿瘤大小通过

Cancer Lett:卡巴他赛聚合物纳米粒子可以用来治疗多烯紫杉醇抗性和骨转运前列腺癌

转移性去势难治性前列腺癌(mCRPC)有效的治疗到目前为止仍旧是一个挑战。卡巴他赛(CBZ)是被批准用于多烯紫杉醇治疗失败的药物,但是生存期的改善仅仅只有大约2个月,并且病人要承受显著的负作用。最近,有研究人员报道了一个关于卡巴他赛的基于聚合物传递系统的开发和研究,目的是提高卡巴他赛的安全性和对DTX抗性mCRPC治疗的有效性。CBZ结合到一种羧甲基纤维素聚合物上(Cellax-CBZ),并且可以